Luxcel Biosciences, Axiogenesis and BMG LABTECH secure €2.5m European investment to develop and launch cell metabolism analysis platform: "MetaCell-TM"

Consortium to advance human iPSC-derived cell-based assay platform for metabolism analysis in preclinical drug discovery and development

Cork, Ireland, Cologne, Germany and Ortenberg, Germany, 15 February 2017: Three European technology SME’s, Luxcel Biosciences Ltd, Axiogenesis AG and BMG LABTECH GmbH, together with two internationally recognised research institutions, Oxford University and Imperial College London, have been awarded €2.5m funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot, to develop and launch a cell metabolism analysis platform that is predicted to be part of routine in vitro cell biology and drug development.

The importance of advanced cell-based assays in preclinical drug discovery and development has risen significantly in recent years, with a major focus on cell metabolism and the use of models that better represent physiological and pathological conditions in cancer, cardiovascular and other diseases. This trend is not surprising considering 10-year timelines, steep costs associated with the development of new drugs (est. c. €2bn per drug) and the link between cell metabolism and drug failure.

Led by Luxcel Biosciences, the consortium will demonstrate a Gold Standard platform, comprising cell assays, disease models and services, together with high performance metabolism tests designed for use on laboratory standard instrumentation - the multi-mode microtiter plate reader.

For Axiogenesis, the advancement of this cell metabolism platform comprises an important strategic fit given that it nicely complements the  currently offered solutions which are mainly functional assays and services. Felix von Haniel, Commercial Director at Axiogenesis, said: "We are very excited to be part of this consortium. It greatly adds to our current portfolio, and broadens our application range in that it focuses not only on the safety / toxicity market, but in particular on drug discovery in the metabolic area. Also, the availability of ready-to-use kits makes iPSC-derived cells more easily accessible to a broader range of users, and is aligned with Axiogenesis’ philosophy to provide easy-to-implement iPSC-derived cells along with validated, physiologically relevant assays."

                     luxcel logo          160106 axio Logo              BMGLogo4c

Continue Reading

Axiogenesis and Metrion Biosciences announce stem cell collaboration

Collaboration to develop human iPSC-derived cardiomyocytes and neurons for translational drug discovery

Cologne, Germany and Cambridge, UK, 07 November 2016: Axiogenesis AG, a preclinical biotechnology company specialising in the development and production of induced pluripotent stem cell (iPSC)-derived cells and tissues for preclinical applications, and Metrion Biosciences Ltd, the specialist ion channel CRO, have signed a collaboration agreement to validate, optimise and commercialise iPSC-derived cell based assays to facilitate drug discovery and more accurately predict cardiac arrhythmia and neuronal risk.

Under the terms of the agreement, Axiogenesis will share newly developed iPS-derived cardiomyocytes and neurons with Metrion for detailed profiling and validation on its high quality screening platforms, and Metrion will use commercial Axiogenesis cell products in its optimised ion channel screening, cardiac safety and translational phenotypic assays.

   160106 axio Logo                    metrion logo curves 2

Continue Reading

FDA publication confirms Cor.4U as most predictive cardiac cell model

Two recent peer-reviewed publications underline the predictive value of Axiogenesis Cor.4U iPSC-derived cardiomyocytes (iPSC-CMs). Key observations and conclusions of these papers are discussed below.

Continue Reading

2016 Application Workshop Material is Available for Download now

We thank our attendees, presenter and cooperation partners for their contribution to the success of this workshop. 

The conference material of our latest Application Workshop, Sept 7- 9, 2016  is available here.

Axiogenesis Secures Major Funding for its Expansion Course

COLOGNE, Germany, May 3, 2016 /PRNewswire/ — Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence.

Sino-German High-Tech Fund (SGHF) is an investment fund jointly supported by Donghai Securities from China and High-Tech Gründerfonds from Germany. Its initiative signing ceremony was chaired by the German Chancellor Angela Merkel and the Chinese Prime Minister Li Keqiang in 2015. Up to 300 million Euro are to be invested in German high-tech companies over the next five years through SGHF, which focuses on high-end manufacturing, renewable energy, bio-technology, TMT and healthcare sectors, etc. With its capital and industry resources, SGHF will strongly support German companies’ market entry and expansion in China as well as their globalization strategies.

For the complete press release, click here (English) or here (German).

 

Recording of CHI's Webinar "Humanizing Early Drug Discovery and Preclinical Safety Testing with Physiological iPS Cell Models"  is online available now

Webinar Description:

Learn how human cardiac cells, derived from induced pluripotent stem cells (iPSC), are playing a rapidly increasing role in in vitro drug discovery & development assays in the pharmaceutical industry. From high-throughput screening (HTS) to toxicology testing, human cardiac cells can be applied in pure 2D cultures for desired controls as well as 3D co-culture systems for physiological relevance. Whether you are screening for new drug targets, or investigating drug effects on electrophysiology, contractility, or cardiac-specific toxicity, this seminar will provide insights for your own research.

Full length recording of the webinar available here

For more details please visit here

 

Cor.4U have electrophysiological parameters approaching adult human tissue

Axiogenesis Cor.4U human cardiomyocytes, serving as a human cellular model in a recent late stage pre-clinical safety study, demonstrated electrophysiological parameters approaching adult human tissue. The use of these Cor.4U cardiomyocytes was “consistent with the emphasis on (Multiple Ion Channel Effects) MICE of the CiPA assay”. The experimental paradigm presented by this study will be a model for future drug safety screening efforts. 

For more details read the full article here

Axiogenesis Sublicenses GE Healthcare iPSC Patents

Axiogenesis AG has sublicensed patents from GE Healthcare to commercialize technologies based on human induced pluripotent stem cells (iPSCs). This solidifies the ability for Axiogenesis and its customers to apply Axiogenesis cell types in the development of cellular assays and stem cell-derived disease models for use in drug discovery and toxicity screening. For the complete press release, click here.

New Axiogenesis Web Site Launched

For the last couple of months, we worked behind the scenes on our new website. Today, we are proud to present to you our new face and welcome you to the Axiogenesis website! The new design enables us to present our growing portfolio and new products clearly arranged. 

Continue Reading

iPSC Neuronal Applications Workshop 2015: Documents Available for Download

The Annual iPSC Neuronal Applications Workshop 2015 was held at the 15th - 17th of April in Cologne at the Axiogenesis headquarters. We thank our 50 attendees, cooperation partners and presenters for their great contribution!

Focusing on our neuronal products Dopa.4UTM and Peri.4UTM, during the symposium data were presented on different assays as dendrite outgrowth (imaging, impedance), Parkinson’s disease model (imaging), toxicology (Multi Electrode Assay), action potential measurement and postsynaptic currents (Patch Clamp).

Continue Reading

Axiogenesis Participates in Global Initiative for Cardiac Safety Assessment

Axiogenesis, a leading global provider of in vitro models of  healthy and diseased human cell types derived from induced pluripotent stem cells (iPSC), has announced its participation in a global effort to demonstrate the utility of human iPSC-derived cardiomyocytes, such as Cor.4U® human cardiomyocytes, as a physiologically-relevant model to predict potentially lethal drug-induced cardiac arrhythmia during the drug development process.

Continue Reading

PhysioStim to Offer Cardiac Safety Studies with Axiogenesis Cor.4U Human iPSC Cardiomyocytes

PhysioStim, a preclinical contract research organization (CRO) located in Lautrec FRANCE, has validated Axiogenesis Cor.4U human induced pluripotent stem cell (hiPSC) derived cardiomyocytes for in vitro cardiac safety studies to the pharmaceutical industry.

For more information, click here.

FDA Researchers Test Axiogenesis Cor.4U Human iPS Cell-Derived Cardiomyocytes

Axiogenesis is pleased to announce that Researchers from the US Food & Drug Administration (FDA) are involved in a defined project to test the Cor.4U® human induced pluripotent stem cell (iPSC)-derived cardiomyocytes within pharmacological assays to predict the safety of drug compounds.

For the complete news release, click here.

  • 1
  • 2

FIND US

Nattermannallee 1, Bldg S20
50829 Cologne
Germany –  (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)

EMAIL US

Orders: order@axiogenesis.com
Support: support@axiogenesis.com
Other: office@axiogenesis.com

FOLLOW US

Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter

CALL US

Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10